Sign In
Last checked at 
11 Jul 2011 07:00
11 July 2011
ValiRx Plc (AIM: VAL)
("ValiRx" or the "Company")
Grant of options
ValiRx, a life science company with a focus on cancer diagnostics and therapeutics for personalised medicine, announces that on 8 July 2011 it granted 42,500,000 options over ordinary shares of 0.1 pence each in the Company ("Ordinary Shares") to certain employees and directors of the Company, as set out in the table below.
Name of director | Number of shares held | % of issued share capital | Number of existing options
| Number of new options granted
| Total options now held | Options held as % of issued share capital
|
Satu Vainikka | 16,644,221 | 1.59% | 1,000,000 | 10,000,000 | 11,000,000 | 1.05% |
Nick Thorniley | 8,213,035 | 0.79% | 400,000 | 6,000,000 | 6,400,000 | 0.61% |
George Morris | 11,409,944 | 1.09% | 750,000 | 6,000,000 | 6,750,000 | 0.65% |
Gerry Desler | 6,154,761 | 0.59% | 400,000 | 6,000,000 | 6,400,000 | 0.61% |
Kevin Alexander | 2,688,750 | 0.26% | 400,000 | 6,000,000 | 6,400,000 | 0.61% |
Oliver de Giorgio-Miller | Nil | Nil | Nil | 3,000,000 | 3,000,000 | 0.29% |
Total Directors | 45,110,711 | 4.32% | 2,950,000 | 37,000,000 | 39,950,000 | 3.82% |
Other employees | Nil | Nil | 600,000 | 5,500,000 | 6,100,000 | 0.59% |
Total | 45,110,711 | 4.32% | 3,550,000 | 42,500,000 | 46,050,000 | 4.41% |
The new options were granted under the Company's stock option plan and have an exercise price of 0.75 pence. The new options are exercisable between 8 July 2011 and 7 July 2021.
Following the grant of the new options, the total number of Ordinary Shares under option held by directors which could be issued is 39,950,000 Ordinary Shares, representing approximately 3.8 per cent. of the current issued share capital of the Company.
In addition, a further 5,500,000 options have been granted to employees of the Company at an exercise price of 0.75 pence which are exercisable until 7 July 2021.
The issued share capital of the Company comprises 1,044,562,609 ordinary shares of 0.1 pence each.
For more information, please contact:
ValiRx plc | www.ValiRx.com |
Dr Satu Vainikka | Tel: +44 (0) 20 3008 4416 |
Cairn Financial Advisers LLP | |
Nominated Adviser | Tel:+44 (0) 20 7148 7900 |
Liam Murray / Avi Robinson | |
Hybridan LLP | |
Broker | Tel: +44 (0) 20 7947 4350 |
Claire Noyce | |
Peckwater PR | Tel: +44 (0)7879 458 364 |
Tarquin Edwards | tarquin.edwards@peckwaterpr.co.uk |
Follow the stocks
